Novavax, Inc.’s vaccine against SARS-CoV-2 is effective at preventing infection with the UK and South African variant strains of the virus, according to new study results, but consistent with other vaccine results, the protection is lower than against the original strain.
The Gaithersburg, MD-based company released data from two studies, a Phase III study in the UK and a Phase IIb...







